BAFF and APRIL protect B-CLL cells from drug-induced apoptosis
. | Patients . | . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 8B . | 10B . | 15C . | 18B . | 19 . | 20 . | 21 . | Mean . | ||||||
| Control | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| F | 2.2 | 2.26 | 4.22 | 1.61 | 6.33 | 5.03 | 1.24 | 3.27* | ||||||
| F + BAFF | 1.04 | 1.85 | 0.68 | 1.57 | 1.29 | 3.8 | 1.08 | 1.62† | ||||||
| F + APRIL | 1.57 | 2.71 | 0.66 | 2.3 | 5.26 | 4.46 | 0.82 | 2.54* | ||||||
| F + BAFF + APRIL | 0.95 | 2.1 | ND | 2.01 | 0.58 | 3.27 | 0.82 | 1.62 | ||||||
. | Patients . | . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 8B . | 10B . | 15C . | 18B . | 19 . | 20 . | 21 . | Mean . | ||||||
| Control | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| F | 2.2 | 2.26 | 4.22 | 1.61 | 6.33 | 5.03 | 1.24 | 3.27* | ||||||
| F + BAFF | 1.04 | 1.85 | 0.68 | 1.57 | 1.29 | 3.8 | 1.08 | 1.62† | ||||||
| F + APRIL | 1.57 | 2.71 | 0.66 | 2.3 | 5.26 | 4.46 | 0.82 | 2.54* | ||||||
| F + BAFF + APRIL | 0.95 | 2.1 | ND | 2.01 | 0.58 | 3.27 | 0.82 | 1.62 | ||||||
Cytoplasm nucleosome enrichment was measured after the addition of soluble BAFF and APRIL (0.25 μg/mL) to cultures of leukemic B cells for 72 hours of incubation in the presence of medium containing 0.2 μM flavopiridol for 7 patients with leukemia. Results are expressed as cytoplasm nucleosome enrichment compared with untreated cells taken as 1 (enrichment of nucleosomes in untreated cells increased approximately 5 times between days 0 and 3 of culture as a consequence of spontaneous apoptosis). F indicates flavopiridol. Probability (.01 ≤ P < .05) is expressed in comparison with untreated (*) or flavopiridol-treated (†) cells.